The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
and so he came to my lab and showed that we could do this in mice we could we could see age-related periodontal disease we could see bone loss around the teeth we could see inflammation of the gums and that we could reverse that with rapamycin
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
so you could easily imagine something similar to the structure of the restore bio trial with rapamycin or everolimus or rtb101 or you know pick your favorite intervention where you treat people for eight weeks three months you know they have a dental exam before a dental exam after a dental exam six months later and you just look and see what was the what was the impact of the the intervention
my lab has published that in that aged mice get periodontal disease that um uh eight weeks of treatment with rapamycin reverses the clinically defining features of periodontal disease in mice
some of the benefits that we've shown in mice from systemic Rapa and treatment on periodon disease gingival inflammation bone growth around the teeth so that's again a tangent from what we were talking about but I think Super interesting and unexplored
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.